Stockreport

ReShape Lifesciences® Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corporate Update

ReShape Lifesciences, Inc.  (RSLS) 
US:NASDAQ Investor Relations: ir.enteromedics.com
PDF Entered into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys Significant Reduction in Overall Operating Expenses of 45.4% in t [Read more]